Baylor College of Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Baylor College of Medicine sits in the top decile of US sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count).
Baylor College of Medicine: 616 sponsored US clinical trials, 93 recruiting.
Baylor College of Medicine sponsors 616 registered US clinical trials on ClinicalTrials.gov, 93 of them currently recruiting, and 376 completed. 59 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Hodgkin Lymphoma, with 7 trials.
Top-decile sponsor footprint
Baylor College of Medicine ranks in the top decile of sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
376 of 452 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
616 total, page 3 of 13
Diagnostic Utility of Otosight Middle Ear Scope
NCT05641285
Super Chef - an Online Program Promoting the Mediterranean Dietary Pattern to Lower Income Families
NCT05863559
Clear Aligners for the Treatment of Dental Malocclusion in OI
NCT04815564
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
NCT05317637
Imaging-Guided Low Intensity Focused Ultrasound (LIFU)
NCT05467085
Efficacy Trial Healthy Dads, Healthy Kids for Hispanic Fathers and Children
NCT05334420
Monopolar and Bipolar Current RFA Knife in POEM
NCT05272046
Monopolar Current Cutting Knife vs Bipolar RFA Knife
NCT04919824
Utility of Advanced Ultrasound Otoscope In The Diagnosis of AOM
NCT06429709
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
NCT04377932
Phase II Adaptive Deep Brain Stimulation for Obsessive-Compulsive Disorder
NCT04806516
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
NCT05103631
Brain Recordings in Patients Undergoing Deep Brain Stimulation (DBS) for Severe Obsessive-Compulsive Disorder (OCD)
NCT05915741
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
NCT04219163
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
NCT03774654
Causal Mechanisms in Adolescent Arterial Stiffness
NCT04128969
Development of Adaptive Deep Brain Stimulation for OCD
NCT04281134
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
NCT03635632
Patch vs. No Patch Fetoscopic Meningomyelocele Repair Study
NCT03794011
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
NCT02932956
Effect of Early Range of Motion Following First Time Patellar Dislocation
NCT04294199
Development of Adaptive Deep Brain Stimulation for OCD (Phase 1a)
NCT03457675
Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)
NCT03459456
Glutathione in Mild Cognitive Impairment
NCT03493178
Oral Care in Infants With Gastroschisis
NCT03393832
Throat and Other HPV-Related Cancers in Men: Identifying Them Early
NCT02897427
Dental Malocclusion and Craniofacial Development in OI
NCT02934451
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
NCT02442297
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
NCT02494167
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
NCT02379520
Urinary Biomarkers of OI Pathobiology
NCT02531087
TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
NCT02065362
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
NCT02287311
International Fetal Anesthesia Database
NCT02591745
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
NCT02050347
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
NCT01953900
3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN
NCT01822652
Morphological Markers of Gastroesophageal Reflux Disease (GERD)
NCT01921686
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
NCT01333046
Post-Discharge Growth of Infants Who Received Donor Human Milk Products in the Neonatal Intensive Care Unit (NICU)
NCT01483079
Administration of Donor T Cells With the Caspase-9 Suicide Gene
NCT01494103
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
NCT01192464
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
NCT01192555
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
NCT00902044
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
NCT00881920
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
NCT00840853
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
NCT00586391
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
NCT00710892
Study of Selected X-linked Disorders: Goltz Syndrome
NCT00691223
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
NCT00368082
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 173 |
| Phase 2 | 59 |
| Phase 3 | 13 |
| Phase 4 | 46 |
Therapeutic Areas
What is open in the Baylor College of Medicine pipeline
93 recruiting of 616 indexed (15% open); 376 completed (61%).
Phase mix: 59 late (III/IV) vs 232 early (I/II) (early-phase heavy).
Top condition: Non-Hodgkin Lymphoma (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Baylor College of Medicine: open-pipeline peers nationwide
Peers matched on 616 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 616 trials (± recruiting share)
- University of Southern California · 617 trials · 16% recruiting
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Rochester · 636 trials · 15% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Stanford University · 15% recruiting · 1,744 trials
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- 59th Medical Wing · 15% recruiting · 20 trials
Related
What to do with this Baylor College of Medicine page
616 registered trials is a research-attention snapshot, not an endorsement of Baylor College of Medicine or any single study.
- 93 of Baylor College of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Hodgkin Lymphoma is the condition Baylor College of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Hodgkin Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Baylor College of Medicine pipeline card: 616 registered trials from official public datasets.Report a data error.